Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Here are some regions that are attracting biotech and pharma companies.